-
公开(公告)号：US20150259424A1
公开(公告)日：2015-09-17
申请号：US14592558
申请日：2015-01-08
Applicant: GENMAB A/S
Inventor： Janine SCHUURMAN , Catharina Emanuele Gerarda HAVENITH , Paul PARREN , Jan G.J. VAN DE WINKEL , Denise Leah WILLIAMS , Jørgen PETERSEN , Ole BAADSGAARD
IPC: C07K16/28 , A61K45/06 , A61N5/06 , C07K16/46 , G01N33/574 , A61K39/395 , C07K16/42
CPC classification number: C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61N5/062 , C07K16/4258 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/56966 , G01N33/57492 , G01N33/6854 , G01N33/6869 , G01N2333/70596 , G01N2333/715 , G01N2333/7155
Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Abstract translation: 公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。
-
公开(公告)号：US20150231235A1
公开(公告)日：2015-08-20
申请号：US14566279
申请日：2014-12-10
Applicant: GENMAB A/S
Inventor： Jan VAN DE WINKEL , Paul PARREN , Yvo GRAUS , Judith OPRINS , Michel DE WEERS , Martine VAN VUGT , Ole BAADSGAARD, D.M.Sc. , Steen LISBY
IPC: A61K39/395 , A61K31/4439 , A61K31/198 , A61K31/573 , A61K31/69
Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
Abstract translation: 本发明涉及使用包含结合CD38的抗体，皮质类固醇和非皮质类固醇化学治疗剂的组合疗法治疗癌症的新方法。
-
公开(公告)号：US20140093454A1
公开(公告)日：2014-04-03
申请号：US13964956
申请日：2013-08-12
Applicant: Genmab A/S
Inventor： Jessica Teeling , Sigrid Ruuls , Martin Glennie , Jan G.J. van de Winkel , Paul Parren , Jørgen Petersen , Ole Baadsgaard , Haichun Huang
IPC: C07K16/28 , A61K45/06 , G01N33/68 , A61K39/395
CPC classification number: C07K16/2887 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/4258 , C07K2317/21 , C07K2317/54 , C07K2317/56 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/92 , G01N33/686
Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Abstract translation: 公开了结合并抑制人CD20的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。
-
94.发明公开公开(公告)号：US20240327544A1
公开(公告)日：2024-10-03
申请号：US18579086
申请日：2022-07-13
Applicant: BIONTECH SE , GENMAB A/S
Inventor： Ugur SAHIN , Alexander MUIK , Sina FELLERMEIER-KOPF , Yali FU , Homer ADAMS, III , Gaurav BAJAJ , Brandon HIGGS , Mark FERESHTEH , Vanessa SPIRES , Jordan BLUM , Patricia GARRIDO CASTRO , Michelle NIEWOOD , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Lars GUELEN , Jost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
CPC classification number: C07K16/468 , A61K2039/505 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76
Abstract: The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.
-
公开(公告)号：US20240317861A1
公开(公告)日：2024-09-26
申请号：US18539509
申请日：2023-12-14
Applicant: GENMAB A/S
Inventor： Isil ALTINTAS , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rik RADEMAKER , Paul PARREN , Bart DE GOEIJ
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/42
CPC classification number: C07K16/2827 , A61K39/3955 , A61K45/06 , A61P35/00 , C07K16/2809 , C07K16/4258 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
Patent Agency Ranking
公开(公告)号：US20240254249A1
公开(公告)日：2024-08-01
申请号：US18481578
申请日：2023-10-05
Applicant: BIONTECH SE , GENMAB A/S
Inventor： Ugur Sahin , Friederike Gieseke , Isil Altintas , David Satijn , Paul Parren
IPC: C07K16/28
CPC classification number: C07K16/2878 , C07K2317/31 , C07K2317/565 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
-
公开(公告)号：US20240174759A1
公开(公告)日：2024-05-30
申请号：US18549346
申请日：2022-03-09
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Yali FU , Homer ADAMS , Gaurav BAJAJ
CPC classification number: C07K16/2878 , A61K9/0019 , A61P35/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/565
Abstract: The present disclosure relates generally to the field of multispecific binding agents for use in therapy, in particular for use in treating cancer, wherein the binding agents bind to human CD40 and to human CD137.
-
公开(公告)号：US20240132620A1
公开(公告)日：2024-04-25
申请号：US18235550
申请日：2023-08-17
Applicant: GENMAB A/S
Inventor： Michel DE WEERS , Yvo GRAUS , Judith OPRINS , Paul PARREN , Jan VAN DE WINKEL , Martine VAN VUGT
IPC: C07K16/40 , A61K39/395 , A61K49/00 , C07K14/705 , C07K16/28 , C12N5/10 , C12N15/63 , G01N33/566
CPC classification number: C07K16/40 , A61K39/3955 , A61K49/0004 , C07K14/70596 , C07K16/2896 , C12N5/10 , C12N15/63 , G01N33/566 , A61K2039/505 , C07K2317/34
Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
-
99.发明授权公开(公告)号：US11932693B2
公开(公告)日：2024-03-19
申请号：US18315686
申请日：2023-05-11
Applicant: BioNTech SE , Genmab A/S
Inventor： Ugur Sahin , Sina Fellermeier-Kopf , Friederike Gieseke , Karsten Beckmann , Claudia Paulmann , Alexander Muik , Ivan Kuzmanov , Esther Cornelia Wilhelmina Breij , Patricia Garrido Castro , Jordan Blum , Lars Guelen , Joost Neijssen , Bart-Jan De Kreuk , Richard Hibbert , Janine Schuurman , Aran Frank Labrijn
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K2317/24 , C07K2317/92
Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
-
100.发明公开公开(公告)号：US20230365693A1
公开(公告)日：2023-11-16
申请号：US18315686
申请日：2023-05-11
Applicant: BioNTech SE , Genmab A/S
Inventor： Ugur SAHIN , Sina FELLERMEIER-KOPF , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Alexander MUIK , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Patricia GARRIDO CASTRO , Jordan BLUM , Lars GUELEN , Joost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K2317/24 , C07K2317/92
Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
-
-
-
-
-
-
-
-
-
Search Results
248
records
(took 0.026 seconds)
